摘要
【目的】观察具有活血化痰功效的中药汤剂对痰瘀内阻型慢性阻塞性肺疾病（简称慢阻肺，COPD）稳定期患者肺功能及生存质量的影响。【方法】采用随机数字表法将60例痰瘀内阻型COPD且病情分级为Ⅰ-Ⅱ级的稳定期患者随机分为治疗组（30例）和对照组（30例）。对照组给予长效茶碱（舒氟美）口服，0．2g/次，每12h服1次；治疗组在口服舒氟美的基础上加服具有活血化痰功效的中药汤剂（陈皮、法半夏、莱菔子、紫苏子、浙贝母、北杏、桃仁、茯苓、毛冬青、白芥子、甘草），每日1剂，疗程6个月。比较两组患者治疗前后肺功能及生存质量的变化情况。【结果】治疗6个月后，两组患者的1S用力呼气量（VFEV1）及其相对值（PVEV1）等肺功能指标与治疗前比较差异均无统计学意义（P〉0．05）；两组间比较，差异也无统计学意义（P〉0．05）。治疗后治疗组生存质量综合评分和因子1（F1）、因子2（F2）、因子3（F3）及因子4（F4）等指标与治疗前比较均有显著性差异（P〈0．05），提示患者生存质量各项指标均有所改善；对照组除凡与治疗前比较差异有显著性（P〈0．05）外，其余各项指标与治疗前比较差异均无显著性（P〉0．05），提示对照组的治疗方案也能稳定患者生存质量各项指标的继续恶化；治疗后两组生存质量各项指标比较差异均有显著性（P〈0．01），提示治疗组在改善患者生存质量方面优于对照组。【结论】活血化痰中药配合长效茶碱能稳定患者的肺功能，改善患者的生存质量，有助于痰瘀内阻型COPD稳定期患者病情的改善。
[ Objective] To observe the effect of blood-activating and phlegm-removing decoctions on pulmonary function and quality of life （QOL） in patients with stable chronic obstructive pulmonary disease （COPD）. [ Methods] Sixty stable COPD （classified at stages of Ⅰ ～ Ⅱ ） patients with internal retention of phlegm and stasis were equally randomized into groups A and B by using random number table. Group B was given oral use of sustained-release theophylline tablet （ SRTT ）, 0.2 g per time, once per 12 hours. Group A additionally received blood-activating and phlegm-removing decoctions （mainly composed of Pericarpium Citri Reticulatae, Rhizoma Pinelliae, Semen Raphani, Fructus Perillae, Bulbus Fritillariae Thunbergii, Semen Armeniacea Amarum, Semen Persicae, Poria, Radix Ilicis Pubescentis, Semen Sinapis Albae, Radix Glycyrrhizac）, one dose per day. The two groups were treated for 6 months. After treatment, the changes of pulmonary function and QOL were compared between the two groups. [ Results] After treatment, pulmonary function indexes such as forced expiratory volume in one second （FEV1） and its relative value （FEV1%） did not differ from those before treatment in both groups （P 〉 0.05）, and the difference was insignificant between groups A and B （ P 〉 0.05）. The differences of comprehensive scoring of QOL and scoring of factors 1, 2, 3 and4 （F1, F2, F3 and F4） in group A were significant as compared with those before treatment （P 〈 0.05）; compared with that before treatment, the difference of F4 was significant in group B （ P 〈 0.01 ）, while that of other indexes was insignificant after treatment （ P 〉 0.05 ）, indicating that oral use of SRTT inhibited the aggravation of pulmonary function. The improvement of QOL in group A was superior to that in group B after treatment and the difference was significant （ P 〈 0.01 ）. [ Conclusion] Oral use of SRTT combined with blood-activating and phlegmremoving herbal medicine can inhibit the aggravation of pulmonary function, improve QOL of COPD patients, and relieve symptoms of stable COPD patients with internal retention of phlegm and stasis.
出处
《广州中医药大学学报》
CAS
2006年第4期275-278,281,共5页
Journal of Guangzhou University of Traditional Chinese Medicine
关键词
肺疾病
慢性阻塞性/中西医结合疗法
活血祛瘀药/治疗应用
化痰药(中药)/治疗应用
用力呼气量/药物作用
生活质量
PULMONARY DISEASE, CHRONIC OBSTRUCTIVE/TCM-WM therapy
DRUGS FOR ACTIVATING BLOOD AND REMOVING STASIS/therapeutic use
EXPECTANTS （TCD） /therapeutic use
FORCED EXPIRATORY VOLUME/drug effects
QUALITY OF LIFE
